Lopinavir/Ritonavir in PLWH With High-Grade AIN

Recruiting Phase 1 Interventional Study
High-Grade Anal Intraepithelial Neoplasia
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Prevention
Participants needed
21 (estimated)
Sponsor
University of Wisconsin, Madison · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on active study for approximately 3 months and long term follow up for 40 weeks.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * willing to provide informed consent * greater than or equal to 18 years of age * Diagnosis of biopsy-confirmed HGAIN * willing to comply with all study procedures Exclusion Criteria: * Diagnosis of low-grade anal dysplasia (AIN, low-grade squamous intraepithelial lesion (LSI…
Contacts

Cancer Connect, MD, FACS

800-622-8922

clinicaltrials@cancer.wisc.edu

CONTACT